A detailed history of Northern Trust Corp transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Northern Trust Corp holds 5,450 shares of MLTX stock, worth $268,467. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,450
Previous 4,877 11.75%
Holding current value
$268,467
Previous $214,000 28.04%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$40.15 - $55.4 $23,005 - $31,744
573 Added 11.75%
5,450 $274,000
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $32,165 - $40,678
-837 Reduced 14.65%
4,877 $214,000
Q1 2024

May 14, 2024

SELL
$43.78 - $63.86 $65,144 - $95,023
-1,488 Reduced 20.66%
5,714 $287,000
Q4 2023

Feb 13, 2024

BUY
$36.35 - $63.02 $53,252 - $92,324
1,465 Added 25.54%
7,202 $434,000
Q3 2023

Nov 13, 2023

BUY
$48.35 - $61.26 $277,383 - $351,448
5,737 New
5,737 $327,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.82B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.